At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 14 enrolled
Drug / intervention
ondansetrondrug
Likely dose
ondansetron 0.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study
In Brief
A Phase 4 clinical trial evaluating ondansetron for Obsessive Compulsive Disorder. Completed, enrolled 14 participants across 1 site.
Detailed Summary
Given that 5-HT3 receptors are indirect inhibitors of cortico-mesolimbic DA release, the 5-HT3 receptor antagonist ondansetron augmentation might potentially have efficacy in the treatment of resistant Obsessive Comulsive Disorder (OCD) patients on combined SRIs and antipsychotics.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive Compulsive Disorder
CountriesItaly
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
Primary CompletionNov 2008
First PostedNov 2008
Study CompletionDec 2008
TodayJul 2026
First PostedNov 24, 2008
Enrollment StartMar 1, 2008
Primary CompletionNov 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.6 years ago
Interventions
ondansetrondrug
ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.